Option chain shows key data for Brainstorm Cell's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Brainstorm Cell.

Brainstorm Cell (NASDAQ:BCLI) Stock, Option Chain

Brainstorm Cell

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

General

BCLI

BRTX

LGVN

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADXN

ANGH

BPTS

BSGM

DXYZ

FAAS

FCUV

GHSI

HALO

HRYU

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MDIA

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

SNGX

VBIV

VINC

WAVE

Shares of  Biophytis S.A.  (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

Intraday Update

ABBV

AEHR

AKAN

BCAN

CIFR

COOT

CYTO

CZOO

EGOX

ESPR

FLGC

FRGE

GDRX

IVVD

JWEL

LABP

LASE

LCID

LDOS

LICN

LICY

LPRO

MASI

MLGO

MSTR

NKTX

OCGN

OKYO

OTRK

SGMT

SINT

SLRX

SOND

STIM

SWVL

URGN

VMEO

XTLB

Shares of  Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent &amp; Trademark Office (USPTO) for patent application 16/981,757 which covers its proprietary exosome technology.&nbsp;

BrainStorm Receives Notice Of Allowance fFr U.S. Patent On Innovative Exosome Platform Technology

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.57) by 10.53 percent.

Earnings

Earnings Beats

Brainstorm Cell Q3 2024 GAAP EPS $(0.51) Beats $(0.57) Estimate

WIIM

PLUR

Brainstorm Cell Therapeutics and Pluri shares are trading higher after the companies entered into a memorandum of understanding to manufacture NurOwn for a Phase 3b trial in amyotrophic lateral sclerosis.

This MOU enables BrainStorm to begin transfer of its manufacturing technology and start producing NurOwn at Pluri's manufacturing facility upon finalizing the binding definitive agreement.

Contracts

BrainStorm Enters Memorandum Of Understanding With Pluri To Manufacture NurOwn For Use In Planned Phase 3b Trial In Amyotrophic Lateral Sclerosis

Health Care

Brainstorm Cell Therapeutics Received Written Notice From The Nasdaq Stock Market Stating That The Company Has Regained Compliance With The Minimum Closing Bid Price Requirement For Continued Listing

BrainStorm Cell Therapeutics Announced The Presentation Of Two Posters Featuring Nurown (MSC-NTF0 Or Debamestrocel) At The 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium Meeting

Brainstorm Cell Therapeutics shares are trading higher after the company announced its CEO will discuss its Phase 3b ALS trial at the Maxim Healthcare virtual summit.

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside Chat at 9:30 a.m. ET on October 15. During the session, Mr. Lebovits will provide an update on the planned Phase 3b clinical trial for NurOwn&#xAE;, the company's investigational cell therapy for ALS. This event presents a valuable opportunity to engage with the investment community and share in-depth insights into the upcoming trial.
&nbsp;
The Maxim Healthcare Summit will take place from October 15 to 17 and will bring together biotechnology, diagnostic, medical device, and healthcare information technology companies. Senior analysts will lead presentations and discussions, while engaging industry panels will focus on critical healthcare trends shaping the future of the industry.

BrainStorm CEO to Discuss Phase 3b ALS Trial at Maxim Healthcare Virtual Summit

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 10.7% to $0.39 during Friday's after-market session. The company's market cap stands at $29.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 10.03% to $5.92. The market value of their outstanding shares is at $3.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock rose 5.86% to $0.74. The company's market cap stands at $111.5 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 5.07% to $0.23. The company's market cap stands at $18.6 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 4.72% to $0.31. The market value of their outstanding shares is at $155.9 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares rose 4.66% to $0.62. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock fell 9.6% to $1.8 during Friday's after-market session. The market value of their outstanding shares is at $45.9 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock declined by 6.53% to $1.11. The company's market cap stands at $40.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 6.1% to $0.46. The market value of their outstanding shares is at $35.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock declined by 6.07% to $0.19. The market value of their outstanding shares is at $10.6 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock decreased by 5.66% to $2.67. The company's market cap stands at $417.9 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares decreased by 5.41% to $0.21. The market value of their outstanding shares is at $8.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELEV

ESLA

EYEN

GANX

Kintara Therapeutics, Inc. - Common Stock

KTRA

OPTN

TCBP

VIRX

ZJYL

12 Health Care Stocks Moving In Friday's After-Market Session

BrainStorm Cell Therapeutics Plans To Share Latest Update On NurOwn At This Year's NEALS Meeting

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 69.23 percent increase over losses of $(0.13) per share from the same period last year.

Brainstorm Cell Q2 2024 GAAP EPS $(0.04), Inline. Cash And Equivalents Of $3.5M

CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commercial Manufacturer; Despite ~5% Value Range Reduction Due To Dilution, Investment Hypothesis Remains &gt;10x Return; Exploring Non-Dilutive Grant Funds

BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS

BrainStorm Cell Therapeutics Says On July 18, Received MVLS Deficiency Notice From Nasdaq Listing Qualifications Department Staff

Maxim Group analyst Jason McCarthy upgrades Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) from Hold to Buy and announces $2 price target.

Upgrades

Price Target

Analyst Ratings

Maxim Group Upgrades Brainstorm Cell to Buy, Announces $2 Price Target

Offerings

BrainStorm Cell Therapeutics Prices $4.0M Registered Direct Offering Of 11,111,111 Shares At $0.36/Share

BrainStorm Cell Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn&#xAE;, its investigational therapy for amyotrophic lateral sclerosis (ALS).

BrainStorm Cell Therapeutics Reaches Alignment With FDA On Chemistry, Manufacturing, And Control Aspects Of Phase 3b NurOwn Clinical Trial For Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of&nbsp;Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of&nbsp;June 18, 2024.
<img alt="BrainStorm Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" />
Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for&nbsp;$73 million&nbsp;in 2022. Dr.&nbsp;Hartounian founded and managed the growth of four biotechnology companies. He has a track record of achieving aggressive goals at large pharmaceutical, contract development and manufacturing organizations, as well as at start-up biotechnology companies.
In his new role, Dr. Hartounian will oversee all operational aspects of BrainStorm Cell Therapeutics, including CMC and commercialization. He has the right skillset to enhance the company&#39;s operational efficiency and the strategic vision to support the commercial readiness of its therapeutic platforms including NurOwn&reg; for amyotrophic lateral sclerosis (ALS).

Management

BrainStorm Cell Therapeutics Taps Haro Hartounian Ph.D. as COO, Effective June 18

<h3>Gainers</h3>
<ul>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock increased by 7.46% to $3.6. The company's market cap stands at $17.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 12.4% to $0.78 during Friday's after-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares fell 11.47% to $3.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock declined by 7.45% to $0.23. The company's market cap stands at $11.0 million. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock declined by 7.38% to $2.01. The company's market cap stands at $59.9 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares decreased by 6.03% to $0.36. The company's market cap stands at $5.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock decreased by 5.49% to $1.55. The company's market cap stands at $228.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTX

BFRG

CANF

CERO

ISPC

NDRA

RENB

SCNI

Press Releases

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market

BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology

BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update

Comments

Brainstorm Cell

Brainstorm Cell (BCLI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga